The estimated Net Worth of Pablo G. Legorreta is at least $72.3 Milione dollars as of 28 June 2023. Mr Legorreta owns over 130,000 units of Royalty Pharma plc stock worth over $16,668,000 and over the last 5 years he sold RPRX stock worth over $0. In addition, he makes $55,674,558 as Founder e Chairman & CEO at Royalty Pharma plc.
Mr has made over 5 trades of the Royalty Pharma plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 130,000 units of RPRX stock worth $3,836,300 on 28 June 2023.
The largest trade he's ever made was buying 230,000 units of Royalty Pharma plc stock on 16 May 2023 worth over $7,677,400. On average, Mr trades about 62,000 units every 111 days since 2019. As of 28 June 2023 he still owns at least 600,000 units of Royalty Pharma plc stock.
You can see the complete history of Mr Legorreta stock trades at the bottom of the page.
Pablo Gerardo Legorreta is the Founder, Chairman & CEO at Royalty Pharma plc.
As the Founder e Chairman & CEO of Royalty Pharma plc, the total compensation of Mr Legorreta at Royalty Pharma plc is $55,674,558. There are no executives at Royalty Pharma plc getting paid more.
Mr Legorreta is 57, he's been the Founder e Chairman & CEO of Royalty Pharma plc since . There are 1 older and 2 younger executives at Royalty Pharma plc. The oldest executive at Royalty Pharma plc is George Wingate Lloyd, 62, who is the Exec. VP of Investments & Gen. Counsel.
Pablo's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK, NY, 10022.
Over the last 4 years, insiders at Royalty Pharma plc have traded over $863,995,127 worth of Royalty Pharma plc stock and bought 5,330,350 units worth $152,553,456 . The most active insiders traders include David C Hodgson, William E Ford e Capital Partners Gp, L.L.C..... On average, Royalty Pharma plc executives and independent directors trade stock every 13 days with the average trade being worth of $7,420,205. The most recent stock trade was executed by Rory B Riggs on 2 January 2024, trading 470,000 units of RPRX stock currently worth $13,221,100.
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi
Royalty Pharma plc executives and other stock owners filed with the SEC include: